Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
← catalyst calendarSponsored by Aclaris Therapeutics, Inc. (industry) · ACRS — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
14actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-19 | actual | When the study began enrolling |
| Primary completion | 2025-03-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-31 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Intervention
- Drug: ATI-2138
Primary outcome
what the primary-completion date above is the date OFIncidence and severity of treatment emergent adverse events (TEAEs)
measured From baseline up to two weeks after treatment (Day 98)
Permalink · ACRS's whole pipeline · Catalyst calendar · Every registered study · What changed